DO-BO

Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier?

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist and Founder of TOWWERS — to make the case for moving early health economics upstream.

The conversation reframes value as more than a financial number: the combination of clinical relevance, economic relevance, and affordability, aligned early across the “five Ps” — patients, prescribers, policymakers, payers, and producers. Björn and Julie explain why early models should be deliberately simple, built to test scenarios and surface the strongest value signals rather than chase false precision, and why embracing uncertainty is a feature, not a flaw. They also tackle the implementation risk too often ignored — illustrated by a CAR-T case in Quebec where it took a full year to treat the first patient after approval — and why an early “no-go” can be just as valuable as a green light.

LinkedIn: Dr. Björn Schwander https://www.linkedin.com/in/bjoern-schwander-phd-672040b/

Julie Frappier https://www.linkedin.com/in/julie-frappier-b5642a3/

Related

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]